1 INTRODUCTION 1.1. OVERVIEW OF THE INTRA-UTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET 1.2. MARKET SEGMENTATION & COVERAGE 1.2.1. CURRENCY AND PRICING 1.2.2. LIMITATION 1.2.3. STAKEHOLDERS 2 RESEARCH METHODOLOGY 2.1. KEY TAKEAWAYS 2.2. ARRIVING AT THE INTRA-UTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET SIZE 2.2.1. MARKET CRACKDOWN APPROACH 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS 2.2.3. DATA TRIANGULATION 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES 2.2.6. PORTER’S FIVE FORCES MATRIX 2.4. GLOBAL INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: RESEARCH SNAPSHOT 2.5. ASSUMPTIONS 3 MARKET LANDSCAPE SUMMARY 4 PREMIUM INSIGHTS 4.1. OVERVIEW 4.2. GLOBAL INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: KEY PRIMARY INSIGHTS 4.3. MARKET OVERVIEW 4.3.1. DRIVERS 4.3.1.1. INCREASING RATE OF UNPLANNED PREGNANCIES 4.3.1.2. POPULATION CONTROL POLICIES 4.3.1.3. RISING INITIATIVES BY THE PRIVATE FIRMS AND NGO’S 4.3.1.4. FAVOURABLE REIMBURSEMENTS 4.3.1.5. GROWING AWARENESS OF CONTRACEPTIVE USAGE 4.3.1.6. GROWING FUNDS AND GRANTS FOR IUCD DEVICES 4.3.1.7. TECHNOLOGICAL ADVANCEMENTS 4.3.2. RESTRAINTS 4.3.2.1. HIGH COST OF TREATMENT 4.3.2.2. THREAT OF CAUSING PELVIC INFLAMMATORY DISEASES (PID) 4.3.2.3. THREAT OF ECTOPIC PREGNANCY 4.3.3. OPPURTUNITIES 4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES 4.3.4. THREATS 4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES 5 EXECUTIVE SUMMARY 6 IUCD MARKET, BY PRODUCT TYPE 6.1. OVERVIEW 6.2. HORMONAL IUCD (2014 – 2022) 6.2.1. MARKET VALUE (USD MILLION) 6.2.2. MARKET VOLUME (UNITS SOLD) 6.3. COPPER IUCD (2014 – 2022) 6.3.1. MARKET VALUE (USD MILLION) 6.3.2. MARKET VOLUME (UNITS SOLD) 7 IUCD MARKET, BY END USER 7.1. OVERVIEW 7.2. HOSPITALS 7.3. GYNECOLOGY CLINICS 7.4. COMMUNITY HEALTHCARE 8 IUCD MARKET, BY GEOGRAPHY 8.1. COUNTRYWISE INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY) 8.1.1. NORTH AMERICA 8.1.1.1. U.S. 8.1.1.2. CANADA 8.1.1.3. MEXICO 8.1.2. EUROPE 8.1.2.1. GERMANY 8.1.2.2. FRANCE 8.1.2.3. U.K. 8.1.2.4. ITALY 8.1.2.5. SPAIN 8.1.2.6. RUSSIA 8.1.2.7. TURKEY 8.1.2.8. BELGIUM 8.1.2.9. NETHERLANDS 8.1.2.10. SWITZERLAND 8.1.2.11. REST OF EUROPE 8.1.3. ASIA-PACIFIC (APAC) 8.1.3.1. JAPAN 8.1.3.2. CHINA 8.1.3.3. SOUTH KOREA 8.1.3.4. INDIA 8.1.3.5. AUSTRALIA 8.1.3.6. SINGAPORE 8.1.3.7. THAILAND 8.1.3.8. MALAYSIA 8.1.3.9. INDONESIA 8.1.3.10. PHILIPPINES 8.1.3.11. REST OF APAC 8.1.4. LATIN AMERICA 8.1.4.1. BRAZIL 8.1.4.2. REST OF LATIN AMERICA 8.1.5. MIDDLE EAST AND AFRICA 8.1.5.1. SOUTH AFRICA 8.1.5.2. REST OF MIDDLE EAST AND AFRICA 8.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES 9 IUCD MARKET: COMPETITIVE LANDSCAPE 9.1. GLOBAL IUCD MARKET: COMPANY SHARE ANALYSIS 9.2. U.S. IUCD MARKET: COMPANY SHARE ANALYSIS 9.3. EUROPE IUCD MARKET: COMPANY SHARE ANALYSIS 9.4. APAC IUCD MARKET: COMPANY SHARE ANALYSIS 9.5. SOUTH AMERICA IUCD MARKET: COMPANY SHARE ANALYSIS 9.6. MIDDLE EAST AND AFRICA IUCD MARKET: COMPANY SHARE ANALYSIS 9.7. MERGERS & ACQUISITIONS 9.8. NEW PRODUCT DEVELOPMENT & APPROVALS 9.9. EXPANSIONS 9.10. REGULATORY CHANGES 9.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS 10 IUCD MARKET, COMPANY PROFILES 10.1 BAYER HEALTHCARE AG 10.1.1 OVERVIEW 10.1.2 SWOT ANALYSIS 10.1.3 PRODUCT PORTFOLIO 10.1.4 REVENUE ANALYSIS 10.1.5 ANALYSTS VIEW 10.2 DKT INTERNATIONAL 10.2.1 OVERVIEW 10.2.2 SWOT ANALYSIS 10.2.3 PRODUCT PORTFOLIO 10.2.4 REVENUE ANALYSIS 10.2.5 ANALYSTS VIEW 10.3 EGEMEN INTERNATIONAL 10.3.1 OVERVIEW 10.3.2 SWOT ANALYSIS 10.3.3 PRODUCT PORTFOLIO 10.3.4 REVENUE ANALYSIS 10.3.5 ANALYST VIEW 10.4 MELBEA AG. 10.4.1 OVERVIEW 10.4.2 SWOT ANALYSIS 10.4.3 PRODUCT PORTFOLIO 10.4.4 REVENUE ANALYSIS 10.4.5 ANALYSTS VIEW 10.5 TEVA PHARMACEUTICALS INDUSTRIES LTD 10.5.1 OVERVIEW 10.5.2 SWOT ANALYSIS 10.5.3 PRODUCT PORTFOLIO 10.5.4 REVENUE ANALYSIS 10.5.5 ANALYSTS VIEW 10.6 ACTAVIS PLC. 10.6.1 OVERVIEW 10.6.2 SWOT ANALYSIS 10.6.3 PRODUCT PORTFOLIO 10.6.4 REVENUE ANALYSIS 10.6.5 ANALYSTS VIEW 10.7 OCON MEDICAL LTD. 10.7.1 OVERVIEW 10.7.2 SWOT ANALYSIS 10.7.3 PRODUCT PORTFOLIO 10.7.4 REVENUE ANALYSIS 10.7.5 ANALYSTS VIEW 10.8 PREGNA INTERNATIONAL LIMITED 10.8.1 OVERVIEW 10.8.2 SWOT ANALYSIS 10.8.3 PRODUCT PORTFOLIO 10.8.4 REVENUE ANALYSIS 10.1.5 ANALYSTS VIEW 10.9 MEDICAL ENGINEERING CORPORATION SA 10.9.1 OVERVIEW 10.9.2 SWOT ANALYSIS 10.9.3 PRODUCT PORTFOLIO 10.9.4 REVENUE ANALYSIS 10.9.5 ANALYSTS VIEW 10.10 SMB CORPORATION 10.10.1 OVERVIEW 10.10.2 SWOT ANALYSIS 10.10.3 PRODUCT PORTFOLIO 10.10.4 REVENUE ANALYSIS 10.10.5 ANALYSTS VIEW 10.10 MERIL LIFE SCIENCES PVT. LTD. 10.10.1 OVERVIEW 10.10.2 SWOT ANALYSIS 10.10.3 PRODUCT PORTFOLIO 10.10.4 REVENUE ANALYSIS 10.10.5 ANALYSTS VIEW 11 APPENDIX 11.1 RELATED REPORTS 11.2 CUSTOMIZABLE OPTIONS 11.3 SOURCE SHEET 11.3 BIBLIOGRAPHY 12 ABOUT DATA BRIDGE MARKET RESEARCH